

Development of AAV-Galanin for Temporal Lobe Epilepsy

ASKLEPIOS BioPharmaceutical Inc (Askbio) is a privately-held clinical-stage company. Askbio is developing a gene delivery technology platform suitable for targeting multiple diseases and multiple tissues, a platform built upon 25+ years of experience developing AAV vectors. This mature IP platform forms a solid foundation for the development of a broad pipeline, and Askbio has a track record of successful collaborations and/or licensing deals with small and large pharma. Askbio is currently developing Galanin gene delivery for the treatment of Temporal Lobe Epilepsy. Proof of concept studies indicate that this approach may have both anti-convulsant and neuroprotective benefits, and is a potentially far less invasive intervention than surgical resection. Askbio is interested in opportunities to support and accelerate the development of galanin gene delivery for epilepsy.